# Bontac Bio-engineering (Shenzhen) Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/bontac-bio-engineering-shenzhen-co

- Industry: Biotechnology
- Headquarters: Shenzhen, China
- Website: www.bontac-bio.com
- Latest round: Series B (Mar 17, 2017)
- Investors on record: 4

## About

Established in 2012 and based in Shenzhen, China, Bontac Bio-engineering (Shenzhen) Co., Ltd. is a biotech company that focuses on the research and development of coenzyme series pharmaceutical intermediates and raw materials. In 2014, the company established a full enzyme catalytic coenzyme production line. In March 2017, the firm closed a series B funding. As of September 2024, it has applied for more than 180 domestic and foreign patents, including more than 170 invention patents.

The company's main products include coenzyme series, natural product series, sugar substitute series, etc. It also provides OEM customization services for cosmetics and health products. The company's products are used in nutrition and health, biomedicine, medical beauty and other fields.

The company’s revenue is generated by providing coenzyme series pharmaceutical intermediates and raw materials.

## Funding rounds

- Series B, Mar 17, 2017 — SZ Capital, Reform Fund
- Series A, Apr 1, 2015 — Fang Fund Partners, Sangel Capital

## Investors

- Fang Fund Partners (https://capitalatlas.ai/funds/fang-fund-partners) — Series A
- Sangel Capital (https://capitalatlas.ai/funds/sangel-capital) — Series A
- SZ Capital — Series B
- Reform Fund (https://capitalatlas.ai/funds/reform-fund) — Series B